Axsome Therapeutics, Inc. (AXSM) Reaches $2.70 After 5.00% Up Move; Domtar (UFS)’s Sentiment Is 1.51

March 27, 2018 - By Migdalia James

Domtar Corporation designs, manufactures, markets, and distributes communication papers, specialty and packaging papers, and absorbent hygiene products in the United States, Canada, Europe, Asia, and internationally. The company has market cap of $2.70 billion. It operates in two divisions, Pulp and Paper, and Personal Care. It currently has negative earnings. The firm provides business papers, including copy and electronic imaging papers that are used with ink jet and laser printers, photocopiers, and plain-paper fax machines, as well as computer papers, preprinted forms, and digital papers for office and home use.

The stock of Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a huge mover today! The stock increased 5.88% or $0.15 during the last trading session, reaching $2.7. About 125,389 shares traded. Axsome Therapeutics, Inc. (NASDAQ:AXSM) has declined 59.08% since March 27, 2017 and is downtrending. It has underperformed by 75.78% the S&P500.The move comes after 5 months positive chart setup for the $68.83 million company. It was reported on Mar, 27 by Barchart.com. We have $2.84 PT which if reached, will make NASDAQ:AXSM worth $3.44 million more.

Among 3 analysts covering Axsome Therapeutics (NASDAQ:AXSM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Axsome Therapeutics had 3 analyst reports since December 14, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, December 15 by Cantor Fitzgerald. Brean Capital initiated Axsome Therapeutics, Inc. (NASDAQ:AXSM) rating on Monday, October 3. Brean Capital has “Buy” rating and $20 target. The stock of Axsome Therapeutics, Inc. (NASDAQ:AXSM) has “Buy” rating given on Monday, December 14 by Ladenburg Thalmann.

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system disorders. The company has market cap of $68.83 million. The companyÂ’s product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and AlzheimerÂ’s disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It currently has negative earnings. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain.

Qv Investors Inc. holds 16.47% of its portfolio in Domtar Corporation for 3.63 million shares. Rock Point Advisors Llc owns 279,985 shares or 5.66% of their US portfolio. Moreover, Fairpointe Capital Llc has 3.24% invested in the company for 3.77 million shares. The Massachusetts-based Mayo Investment Advisers Llc has invested 1.7% in the stock. Amg Funds Llc, a Connecticut-based fund reported 50,440 shares.

The stock decreased 0.67% or $0.29 during the last trading session, reaching $43.05. About 136,243 shares traded. Domtar Corporation (UFS) has declined 0.68% since March 27, 2017 and is downtrending. It has underperformed by 17.38% the S&P500.

Analysts await Domtar Corporation (NYSE:UFS) to report earnings on April, 26. They expect $0.70 EPS, up 118.75% or $0.38 from last year’s $0.32 per share. UFS’s profit will be $43.89M for 15.38 P/E if the $0.70 EPS becomes a reality. After $0.64 actual EPS reported by Domtar Corporation for the previous quarter, Wall Street now forecasts 9.37% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Migdalia James

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: